You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
點亮環球疫情的新希望:君實生物(01877.HK)全力推進新冠中和抗體,搶灘疫苗市場
格隆匯 04-28 12:21

4月27日,國務院新聞辦公室舉行的會議上,多位專家介紹了新冠肺炎疫情相關科學研究情況,指出現階段血漿等治療手段在中國取得了比較好的療效。其中,來自中國科學院微生物研究所的研究員嚴景華,提出另一種中和抗體療法。中和抗體比血漿更容易生產、靶標也更明確。從目前的情況來看,動物實驗結果非常好,預防和保護都很好,毒理上看也非常安全。在疫苗出來之前,有機會成為很好的一個治療方法。

中和抗體(Neutralizing Antibody)是一種可通過中和或抑制病原體(例如病毒)的生物學活性來保護細胞免受侵害的治療性抗體。抗體療法具備多種優勢,能夠同時用於治療和預防;由於人源化抗體對病原體具有高度的特異性,在安全性上有所保障;與痊癒病人血清相比,抗體可以通過工程化實現藥物量產,從而保證臨牀大量應用。

早在三月下旬,君實生物(01877.HK)已宣佈與中國科學院微生物研究所簽訂了項目合作協議,擬共同開發生產新型冠狀病毒中和抗體,提供治療COVID-19的創新型藥物。君實生物的首席運營官馮輝在3月31日的一場投資者交流會上透露,已獲得兩個具有高親和力的新冠病毒中和抗體,具備單獨臨牀或聯合臨牀的潛力。目前正在國內科研機構進行更多體外研究和安全性評價,並與各國監管機構協商開展試驗。同時,為了保證下一步大規模生產的順利實施,廠房將通過2000升反應器進行生產。君實生物副總經理姚盛則表示,新冠中和抗體的研究目前在公司的整體佈局中處於優先地位,保證中和抗體能儘快進入臨牀。

作為目前唯一由中國研究機構和上市企業合作開展,並進入動物實驗環節的中和抗體,這項應用已進入關鍵環節,有望實現產業化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account